IDEXX Laboratories delivered strong Q4 2025 results, with revenue increasing 14% as reported (12% organic) and EPS reaching $3.08, up 17% on a comparable basis. Full-year performance was solid, achieving 10% organic revenue growth and EPS of $13.08 (+14% comparable), driven by an 8% increase in CAG Diagnostics recurring revenue and record premium instrument placements, including nearly 6,400 InVue DX systems. The company successfully navigated a challenging veterinary visit environment, outperforming sector visit trends by 1,100 basis points through increased diagnostic frequency and pricing. Looking ahead to 2026, IDEXX provided guidance for revenue of $4.632B-$4.72B (+7-9% organic) and EPS of $14.29-$14.80, reflecting confidence in its innovation pipeline and commercial expansion despite anticipated headwinds from lapping instrument revenue and persistent macro pressures on wellness visits.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue Growth (Organic) | 12% | +12% YoY |
| Q4 EPS | $3.08 | +17% (Comparable) |
| Full Year 2025 Organic Revenue Growth | 10% | +10% YoY |
| Full Year 2025 EPS | $13.08 | +14% (Comparable) |
| CAG Recurring Revenue Growth (Q4) | 10% | +10% Organic |
| InVue DX Placements (Full Year) | ~6,400 | Record Level |
| 2026 Revenue Guidance | $4.632B - $4.72B | +7.6% to 9.6% Reported |
| 2026 EPS Guidance | $14.29 - $14.80 | +10% to 14% Comparable |
Innovation as a Primary Growth Driver: Management emphasized the success of new platforms, specifically InVue DX and the Catalyst menu expansions. InVue DX placements reached nearly 6,400 for the full year, contributing over $75 million in revenue. The upcoming launch of Fine Needle Aspirate (FNA) analysis on InVue DX and the expansion of the CancerDx panel to include mast cell tumors demonstrate a robust pipeline designed to drive consumable sales and deepen customer integration.
Commercial Footprint Expansion: IDEXX completed a strategic expansion of its commercial team in key international regions (Germany, UK, Australia) and the US. By reducing the account-to-rep ratio, the company aims to drive higher diagnostics adoption and deepen customer relationships. This investment is already yielding results, with international CAG recurring revenue growing 12% in Q4.
Resilience Through Utilization: Despite a 1.9% decline in US same-store clinical visits for the full year, IDEXX grew diagnostic frequency (tests per visit). Management highlighted that non-wellness visits (which drive 70-75% of diagnostics revenue) are more resilient and that the aging pet population ('pandemic puppies') is showing 'green shoots' with improving visit growth for canines five-plus years old.
Software Ecosystem Synergy: The software segment, particularly pet owner engagement tools like Velo, is becoming a strategic differentiator. Velo users grew over 40% quarter-over-quarter, and management noted that clinics using these tools see increased visit frequency and diagnostic compliance. This 'sticky' ecosystem reinforces hardware and consumable sales, creating a competitive moat.
Persistent Veterinary Visit Declines: US same-store clinical visits declined 1.9% for the full year 2025 and 1.7% in Q4, with wellness visits down 3.6% in Q4. Management attributes this to macroeconomic pressures on lower-income households and has incorporated a further 2% decline assumption into 2026 guidance, indicating no immediate recovery is expected.
Moderating Pricing Power: Net price realization is expected to moderate to approximately 3.5% in the US for 2026, down from roughly 4% in 2025. Management noted that corporate practices are moderating price increases to drive traffic, suggesting a potential limit on IDEXX's ability to raise prices aggressively in a constrained consumer environment.
Instrument Revenue Headwinds: The 2026 outlook explicitly anticipates a decline in CAG instrument revenues as the company laps the rapid expansion of InVue DX placements. This shift from a tailwind to a headwind requires stronger consumable growth to maintain overall revenue targets, introducing execution risk.
Guidance Deceleration: The 2026 organic revenue growth guidance of 7-9% represents a deceleration from the 10%+ achieved in 2025. While management frames this as a 'solid' outlook, it implies that the massive innovation boost from 2025 will normalize, requiring the company to find new growth vectors to re-accelerate.
Overall: Management conveyed a high level of confidence and pride in the company's execution, characterizing 2025 as a 'defining year' with 'exceptional execution.' While they acknowledged macro headwinds affecting veterinary visit volume, their demeanor remained optimistic regarding the durability of the business model and the 'green shoots' from the aging pet population. They were direct and detailed in discussing financials and strategy, shifting to a cautious but pragmatic tone when discussing market constraints.
Confidence: HIGH - Management provided specific metrics, detailed guidance ranges, and articulated clear strategic drivers. Their language was decisive regarding innovation success ('transformational platform,' 'exceptional execution') and commercial execution, while maintaining a realistic outlook on external factors.
$4.632 billion to $4.72 billion (7.6% to 9.6% reported, 7% to 9% organic)
$14.29 to $14.80 per share (10% to 14% comparable growth)
8% to 10% organic
32.0% to 32.5% reported (30 to 80 bps comparable improvement)
11.5% to 13.5% reported (9% to 11% organic)
Hedging & Uncertainty: Management primarily used hedging language regarding the external market environment and veterinary visit trends. Phrases like 'we're planning for,' 'we expect,' and 'incorporates expectations for' were used to frame guidance. They notably hedged the timing of a recovery in visit volume, stating they kept the 2% decline baseline 'until, you know, I think until we have clear evidence that that's gonna improve.' However, regarding their internal execution and innovation, language was direct and assertive ('exceptional execution,' 'transformational platform'), indicating high confidence in their ability to control what they can despite macro uncertainty.
In many respects, 2025 was a defining year for our company. - Jay Mazelsky, CEO
The human-animal bond continues to deepen and pet owners remain committed to providing a high standard of care... - Jay Mazelsky, CEO
We're providing initial guidance for revenue of $4.632 billion to $4.72 billion... reflecting 7% to 9% organically. - Andrew Emerson, CFO
We think that likely reflects the pandemic adoption boom and these pets aging. - Jay Mazelsky, CEO
We're planning for about 2% decline until, you know, I think until we have clear evidence that that's gonna improve. - Jay Mazelsky, CEO
The rollout of InVue DX represents one of the most successful product launches in IDEXX history. - Jay Mazelsky, CEO
Analyst Sentiment: Analysts were generally inquisitive and focused on the sustainability of growth amidst sector headwinds. Questions centered on the divergence between wellness and non-wellness visits, the specific financial contributions of new innovations (InVue, CancerDx), and the trajectory of pricing power in a moderating inflation environment.
Management Responses: Management was well-prepared and data-driven in their responses. They effectively shifted the focus from negative visit volume metrics to positive 'quality' metrics like diagnostic frequency and utilization per visit. They provided concrete details on innovation adoption rates and commercial execution to reassure investors about the growth trajectory.
Veterinary Visit Trends: Analysts sought clarity on the divergence between wellness and non-wellness visits and the 'green shoots' from aging pets. Management emphasized the resilience of non-wellness visits and the 'quality' of visits (higher testing frequency).
Innovation Contribution: Analysts asked for quantification of the revenue impact from InVue and CancerDx. Management highlighted the 'leveraged impact' of innovation across the portfolio rather than just standalone revenue, noting InVue's $75M contribution and the potential for CancerDx.
Pricing Power: Questions focused on the moderation of price increases in 2026. Management explained that while inflation is subsiding, they are returning to a more historical baseline, balancing price with volume recovery.
IDEXX continues to demonstrate the strength of its 'razor-and-blade' model with a resilient recurring revenue stream that is growing faster than the underlying market volume. The successful integration of high-growth innovations like InVue DX and CancerDx, combined with a strategic commercial expansion, positions the company to outperform even in a challenging macro environment. While the 2026 guidance implies a slight deceleration due to lapping the InVue launch and persistent visit headwinds, the focus on diagnostic frequency and the aging pet population provides a strong structural growth tailwind. The company's ability to expand margins while investing in growth underscores its operational excellence and competitive moat.
US same-store clinical visits declined 1.9% in 2025, with wellness visits down 3.6% in Q4. Management attributes this to macroeconomic pressures on lower-income households, indicating a persistent softness in the sector that is not expected to recover immediately.
Vet service price inflation is moderating but remains above CPI. Management noted that corporate practices are becoming more price-sensitive to drive traffic, which may limit future price increases for suppliers like IDEXX, leading to a guide of ~3.5% price realization for 2026.
The 'pandemic puppy' boom is aging, leading to 'green shoots' in visit growth for pets 5+ years old. Management believes this demographic shift will support diagnostic utilization as older pets require more frequent and intensive care.